Syndromes and complications of interferon therapy

Current Opinion in Rheumatology

Volumn 19, Issue 1, 2007, Pages 61-66

  Borg, Frances A Y ^a,b   Isenberg, David A ^a  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^b UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

Author keywords

Autoimmunity; Complication; Interferon; Systemic lupus erythematosus; Thyroid

Indexed keywords

CYCLOPHOSPHAMIDE; GAMMA INTERFERON; PLACEBO; RECOMBINANT ALPHA INTERFERON; RECOMBINANT BETA INTERFERON; STEROID; THYROID ANTIBODY;

ANTIBODY SPECIFICITY; ANTIBODY TITER; AUTOIMMUNE DISEASE; AUTOIMMUNE HEPATITIS; AUTOIMMUNE SKIN DISEASE; BULLOUS DERMATITIS; CELIAC DISEASE; COHORT ANALYSIS; DIABETES MELLITUS; DISEASE EXACERBATION; FOLLOW UP; GLOMERULONEPHRITIS; HASHIMOTO DISEASE; HEMATOLOGIC MALIGNANCY; HEMOLYSIS; HEPATITIS C; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; IMMUNOTHERAPY; INFLAMMATORY ARTHRITIS; INSULIN DEFICIENCY; INSULIN DEPENDENT DIABETES MELLITUS; INTERFERON PRODUCTION; JUVENILE RHEUMATOID ARTHRITIS; KIDNEY CARCINOMA; LUNG DISEASE; MELANOMA; MULTIPLE MYELOMA; MULTIPLE SCLEROSIS; MYASTHENIA GRAVIS; MYOSITIS; NEUROPATHY; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; REACTIVE ARTHRITIS; REVIEW; SARCOIDOSIS; SKIN DISEASE; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA; THYROID DISEASE; VASCULITIS; VIRUS HEPATITIS; VITILIGO;

ARTHRITIS; AUTOIMMUNE DISEASES; DIABETES MELLITUS, TYPE 1; HUMANS; INTERFERON TYPE I, RECOMBINANT; INTERFERON-GAMMA, RECOMBINANT; INTERFERONS; LUPUS ERYTHEMATOSUS, SYSTEMIC; RHEUMATIC DISEASES; SYNDROME; THYROIDITIS, AUTOIMMUNE;

EID: 33845357261     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/BOR.0b013e328010c547     Document Type: Review

References (52)

1. Okanoue T, Sakamoto S, Itoh Y, et al. Side effects of high-dose interferon therapy for chronic hepatitis C. J Hepatol 1996; 25:283-291.
2. Ronnblom LE, Alm GV, Oberg KE. Autoimmunity after alpha interferon therapy for malignant carcinoid tumors. Ann Int Med 1991; 115:178-183.
3. Bargiggia S, Thorburn D, Anderloni A, et al. Is interferon-alpha therapy safe and effective for patients with chronic hepatitis C and inflammatory bowel disease? A case-control study. Aliment Pharmacol Ther 2005; 22:209-215.
4. Muratori P, Muratori L, Verucchi G, et al. Nonorgan specific autoantibodies in children with chronic hepatitis C: clinical significance and impact on interferon treatment. Clin Infect Dis 2003; 37:1320-1326.
5. Noda K, Enomoto N, Arai K, et al. Induction of antinuclear antibody after interferon therapy in patients with type-C chronic hepatitis: its relation to the efficacy of therapy. Scand J Gastroenterol 1996; 31:716-722.
6. Huang J-F, Chuang W-L, Dai C-Y, et al. The role of thyroid autoantibodies in the development of thyroid dysfunction in Taiwanese chronic hepatitis C patients with interferon-alpha and ribavirin combination therapy. J Viral Hepatitis 2006; 13:396-401. In a large cohort of patients, antithyroid antibodies precede the development of hormonal dysfunction. Hormonal dysfunction can be managed without the discontinuation of interferon therapy.
7. Monzani F, Caraccio N, Dardano A, Ferrannini E. Thyroid autoimmunity and dysfunction associated with type I interferon therapy. Clin Exp Med 2004; 3:199-210.
8. Boxall EH, Sira J, Ballard AL, et al. Long-term follow-up of hepatitis B carrier children treated with interferon and prednisolone. J Med Virol 2006; 78:888-895. In contrast to hepatitis C-infected patients, hepatitis B carriers did not develop autoimmune disease over a 10-year follow-up.
9. Mandac JC, Chaudhry S, Sherman KE, Tomer Y. The clinical and physiological spectrum of interferon-alpha induced thyroiditis: towards a new classification. Hepatology 2006; 43:661-672. A comprehensive review of IFNα-induced thyroid disease.
10. Doi F, Kakizaki DF, Takagi H, et al. Long-term outcome of interferon-α-induced autoimmune thyroid disorders in chronic hepatitis C. Liver Int 2005; 25:242-246.
11. Mazziotti G, Sorvillo F, Piscopo M, et al. Innate and acquired immune systemin patients developing interferon-α-related autoimmune thyroiditis: a prospective study. J Clin Endocrinol Metab 2005; 90:4138-4144. An important study looking at the cellular basis to the clinically observed thyroid disease. Th2 mechanisms seem to be important in the onset and maintenance of thyroid autoantibody development. Development of clinical disease, however, is associated with a change to a Th1 picture.
12. Levy-Bohbot N, Young J, Orgiazzi J, et al. Interferon-α-induced hyperthyroidism: a three-stage evolution from silent thyroiditis towards Graves' disease. Eur J Endocrinol 2006; 154:367-372. Silent thyroiditis is a well recognized autoimmune complication of IFNα therapy. Here the development of further autoimmune thyroid disease follows thyroiditis.
13. Deutsch M, Koskinas J, Tzannos K, et al. Hashimoto encephalopathy with pegylated interferon alfa-2b and ribavirin. Ann Pharmacother 2005; 39:1745-1747.
14. Fabris P, Floreani A, Tositti G. Review article: type 1 diabetes mellitus in patients with chronic hepatitis C before and after interferon therapy. Aliment Pharmacol Ther 2003; 18:549-558.
15. Cozzolongo R, Betterle C, Fabris P, et al. Onset of type 1 diabetes mellitus during peginterferon α-2b plus ribavirin treatment for chronic hepatitis C. Eur J Gastroenterol Hepatol 2006; 18:689-692.
16. Oishi A, Miyamoto K, Kashii S, Yoshimura N. Retinopathy is not the only ocular symptom: myasthenia gravis in association with interferon therapy. Br J Ophthalmol 2005; 89:1542-1543.
17. Cammarota G, Cuoco L, Cianci R, et al. Onset of coeliac disease during treatment with interferon for chronic hepatitis C. Lancet 2000; 356:1494-1495.
18. Sezaki H, Arase Y, Tsubota A, et al. Type C-chronic hepatitis patients who had autoimmune phenomenon and developed jaundice during interferon therapy. J Gastroenterol 2003; 38:493-500.
19. Guillot B, Blazquez L, Bessis D, et al. A prospective study of cutaneous adverse events induced by low-dose alpha-interferon treatment for malignant melanoma. Dermatology 2004; 208:49-54.
20. Lambotte O, Gelu-Simeon M, Maigne G, et al. Pegylated interferon alpha 2-a-associated life-threatening Evans' syndrome in a patient with chronic hepatitis C. J Infection 2005; 51:e113-e115.
21. Nissen MJ, Fontanges E, Allam Y, et al. Rheumatological manifestations of hepatitis C: incidence in a rheumatology and nonrheumatology setting and the effects of methotrexate and interferon. Rheumatology 2005; 44:1016-1020. Hepatitis C is complicated by rheumatological symptoms. This study explores these symptoms and looks at the role of IFNα and methotrexate in these cases.
22. Niewold TB, Swedler WI. Systemic lupus erythematosus arising during interferon-alpha therapy for cryoglobulinemic vasculitis associated with hepatitis C. Clin Rheumatol 2005; 24:178-181. A case report and in-depth review of the existing case reports.
23. Fritz M, Vats K, Goyal R. Neonatal lupus and IUGR following alpha-interferon therapy during pregnancy. J Perinatol 2005; 25:552-554.
24. Carmonma-Soria I, Jimenez-Saenz M, Gonzalez-Vilches J, Herrerias-Gutierrez JM. Development of lupic anticoagulant during combination therapy in a patient with chronic hepatitis C. J Hepatol 2001; 34:965-967.
25. Nesher G, Ruchlemer R. Alpha-interferon-induced arthritis: clinical presentation, treatment and prevention. Semin Arthritis Rheum 1998; 27:360-365.
26. Beuthien W, Mellinghoff H-U, von Kempis J. Vasculitic complications of interferon-α treatment for chronic hepatitis C virus infection: case report and review of the literature. Clin Rheumatol 2005; 24:507-515. A case report and good review of the existing literature on hepatitis C, IFNα therapy and vasculitis.
27. Alazemi S, Campos MA. Interferon-induced sarcoidosis. Int J Clin Pract 2006; 60:201-211. An extensive review of the existing case literature of interferon-induced sarcoidosis.
28. Hirano A, Kataoka M, Nakata Y, et al. Sarcoidosis occurring after interferon-α therapy for chronic hepatitis C: report of two cases. Respirology 2005; 10:529-534.
29. Venezia G, Licata A, Di Marco V, et al. Acute polymyositis during treatment of acute hepatitis C with pegylated interferon alpha-2b. Dig Liver Dis 2005; 37:882-885.
30. Rio J, Tintore M, Nos C, et al. Interferon beta in relapsing-remitting multiple sclerosis - an eight years experience in a specialist multiple sclerosis centre. J Neurol 2005; 252:795-800. A large follow-up study of 495 multiple sclerosis patients treated with IFN1a and IFNβ2. No autoimmune complications were observed.
31. Coppola G, Lanzillo R, Florio C, et al. Long-term clinical experience with weekly interferon beta-1a in relapsing multiple sclerosis. Eur J Neurol 2006; 13:1014-1021.
32. Collard RC, Koehler PM, Mattson DH. Frequency and significance of antinuclear antibodies in multiple sclerosis. Neurology 1997; 49:857-861.
33. Verdun E, Isoardo G, Oggero A, et al. Autoantibodies in multiple sclerosis patients before and during IFN-b1b treatment: are they correlated with the occurrence of autoimmune diseases? J Interferon Cytokine Res 2002; 22:245-255.
34. Polman CH, Kappos L, Dahlke F, et al. Interferon beta-1b treatment does not induce autoantibodies. Neurology 2005; 64:996-1000. Although de-novo autoantibodies are produced during IFNβ therapy, this is not significantly different from baseline.
35. Caraccio N, Dardano A, Manfredonia F, et al. Long-term follow-up of 106 multiple sclerosis patients undergoing interferon-β 1a or 1b therapy: predictive factors of thyroid disease development and duration. J Clin Endocrinol Metab 2005; 90:4133-4137. A large study into the presence and development of thyroid autoantibodies in IFNβ-treated patients and their relationship to laboratory thyroid dysfunction over 7 years. Both antithyroid autoantibodies and endocrine dysfunction can complicate IFNβ therapy, with the presence of autoantibodies predicting the future emergence of thyroid dysfunction.
36. Durelli L, Ferrero B, Oggero A, et al. Thyroid function and autoimmunity during interferon β-1b treatment: a multicenter prospective study. J Clin Endocrinol Metab 2001; 86:3525-3532.
37. Nousari HC, Kimyai-Asadi A, Tausk FA. Subacute cutaneous lupus erythematosus associated with interferon beta-1a. Lancet 1998; 352:1825-1826.
38. Crispin JC, Diaz-Jouanen E. Systemic lupus erythematosus induced by therapy with interferon-β in a patient with multiple sclerosis. Lupus 2005; 14:495-496. The first report of systemic lupus erythematosus complicating IFNβ therapy has only been reported in the past year.
39. Schwarting A, Paul K, Tschirner S, et al. Interferon-β: a therapeutic for autoimmune lupus in MRL-Fas mice. J Am Soc Nephrol 2005; 16:3252-3272. Administration of IFNβ ameliorates a murine model of SLE with nephritis splenomegaly and skin involvement. Proinflammatory and profibrotic cytokines are down-regulated locally in renal tissue, but no change in Th1:Th2 balance is seen in peripheral blood.
40. Strueby L, Nair B, Kirk A, Taylor-Gjevre RM. Arthritis and bursitis in multiple sclerosis patients treated with interferon-beta. Scand J Rheumatol 2005; 34:485-488. A case report, useful review and comparison of all the current existing reports of IFNβ-associated inflammatory arthritis.
41. Jabaily JA, Thompson JS. Effects of interferon beta-1B in rheumatoid arthritis: a case report [letter]. Arthritis Rheum 1997; 40:1370.
42. Van Holten J, Pavelka K, Vencovsky J, et al. A multicentre, randomised, double blind, placebo controlled phase II study of subcutaneous interferon beta-1a in the treatment of patients with active rheumatoid arthritis. Ann Rheum Dis 2005; 64:64-69.
43. Dionisiotis J, Zoukos Y, Thomaides T. Development of myasthenia gravis in two patients with multiple sclerosis following interferon β treatment. J Neurol Neurosurg Psychiatry 2004; 75:1076-1079.
44. Bobbio-Pallavicini E, Valsecchi C, Tacconi F, et al. Sarcoidosis following beta-interferon therapy for multiple myeloma. Sarcoidosis 1995; 12:140-142.
45. Safdar A, Rodriguez G, Ohmagari N, et al. The safety of interferon-γ-1b therapy for invasive fungal infections after hematopoietic stem cell transplantation. Cancer 2005; 103:731-739.
46. Muir AJ, Sylvestre PB, Rockey DC. Interferon gamma-1b for the treatment of fibrosis in chronic hepatitis C infection. J Viral Hepatitis 2006; 13:322-328.
47. Graininger WB, Hassfeld W, Pesau BB, et al. Induction of systemic lupus erythematosus by interferon-γ in a patient with rheumatoid arthritis. J Rheumatol 1991; 18:1621-1622.
48. Ronnblom L, Eloranta M-L, Alm GV. The type I interferon system in systemic lupus erythematosus. Arthritis Rheum 2006; 52:408-420. A state-of-the-art overview of the current ideas of the role of type 1 interferon in normal immune physiology and in autoimmune disease, with emphasis on novel developments in SLE.
49. Zhuang H, Narain S, Sobel E, et al. Association of antinucleoprotein autoantibodies with upregulation of type I interferon-inducible gene transcripts and dendritic cell maturation in systemic lupus erythematosus. Clin Immunol 2005; 117:238-250. This study demonstrates high levels of IFNα in response to small nuclear proteins in SLE patient blood, which upregulates the expression of interferon-induced genes.
50. Lovgren T, Eloranta M-L, Kastner B, et al. Induction of interferon a by immune complexes or liposomes containing systemic lupus erythematosus autoantigen- and Sjörgren's syndrome autoantigen-associated RNA. Arthritis Rheum 2006; 54:1917-1927. An elegant series of experiments showing that nucleoprotein products and SLE patient-derived IgG are necessary to stimulate IFNa production. IFNγRIII and Toll-like receptor are needed to mediate this process.
51. Hua J, Kirou K, Lee C, et al. Functional assay of type I interferon in systemic lupus erythematosus and association with anti-RNA binding protein antibodies. Arthritis Rheum 2006; 54:1906-1916. A new functional assay for type I interferon is described. The authors also demonstrated that IFNα is responsible for interferon-inducible gene activity in lupus by use of antibodies specific to the different types of type I and II interferons.
52. Shirota H, Ishii KJ, Takakuwa H, Klinman DM. Contribution of interferon-β to the immune activation induced by double-stranded DNA. Immunology 2006; 118:302-310. In contrast to the above study by Hua et al., this study shows that IFNβ is expressed in the cellular response to DNA, and that anti-IFNβ antibodies block up-regulation of CD40 cells and a panel of chemokines.